Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Down 20.8% in February

Hims & Hers Health, Inc. (NYSE:HIMS) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 46,120,000 shares, a decrease of 20.8% from the January 31st total of 58,210,000 shares. Based on an average daily volume of 18,950,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately 25.4% of the shares of the stock are sold short.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded down $0.07 during trading on Tuesday, reaching $40.62. 24,391,218 shares of the company traded hands, compared to its average volume of 12,931,300. Hims & Hers Health has a 1-year low of $11.20 and a 1-year high of $72.98. The company has a 50 day moving average price of $37.08 and a 200-day moving average price of $27.17. The firm has a market capitalization of $9.02 billion, a PE ratio of 92.31 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Equities research analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Leerink Partners boosted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Finally, Bank of America upped their price objective on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research note on Thursday, February 20th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $37.23.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the transaction, the chief executive officer now directly owns 97,687 shares in the company, valued at $5,692,221.49. This represents a 56.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Chi sold 7,259 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $32.25, for a total transaction of $234,102.75. Following the transaction, the insider now owns 184,947 shares of the company’s stock, valued at approximately $5,964,540.75. This represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,062,011 shares of company stock worth $36,892,724 in the last three months. 17.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HIMS. Farallon Capital Management LLC raised its holdings in Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock worth $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after buying an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Yong Rong HK Asset Management Ltd acquired a new position in Hims & Hers Health during the fourth quarter worth $41,104,000. Finally, Renaissance Technologies LLC raised its holdings in Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.